Description
Tsc-203-a0201 is an experimental therapy being studied in clinical trials for certain types of solid tumors, including colorectal cancer. It is a type of immunotherapy called a TCR-T cell therapy. This therapy involves collecting a patient's own immune cells (T cells), modifying them in a lab to better recognize and attack cancer cells, and then infusing these modified cells back into the patient. Specifically, Tsc-203-a0201 is designed to target a protein called PRAME, which is found on some cancer cells. Patients must have specific genetic markers (HLA type) and their tumors must express the target protein (PRAME) to be eligible for this treatment. It is being tested in Phase 1 trials, often in combination with other TCR-T therapies, to determine its safety and potential effectiveness.
Mechanism of Action
Tsc-203-a0201 is a T-cell receptor (TCR) T-cell therapy. It involves engineering a patient's T cells to express a specific TCR that recognizes a specific protein (PRAME) found on the surface of cancer cells. After manufacturing, these modified T cells are infused back into the patient. The goal is for these engineered T cells to find and destroy cancer cells that display the target protein (PRAME). The specific protein target is PRAME.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.